PMID- 11796404
OWN - NLM
STAT- MEDLINE
DCOM- 20020212
LR  - 20220409
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 61
IP  - 2
DP  - 2002 Feb
TI  - Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: 
      relationship with synovitis and steroid treatment.
PG  - 161-6
AB  - OBJECTIVE: To determine matrix metalloproteinase-3 (MMP-3) serum levels in 
      patients with rheumatic diseases and to study the relation between MMP-3 and C 
      reactive protein (CRP) levels. METHODS: MMP-3 serum levels were determined by 
      enzyme linked immunosorbent assay (ELISA) in (a) patients with active 
      inflammatory rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis, 
      polymyalgia rheumatica, acute crystal arthritis, and ankylosing spondylitis; (b) 
      patients with active inflammatory systemic diseases: cutaneo-articular or renal 
      systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitides; (c) 
      patients with non-inflammatory rheumatic diseases: osteoarthritis and 
      fibromyalgia; (d) critically ill patients without rheumatic diseases, 
      representing an acute inflammatory control group; (e) healthy controls. RESULTS: 
      MMP-3 serum levels were significantly increased in patients with active RA, 
      psoriatic arthritis, and polymyalgia rheumatica, whether treated or not by 
      corticosteroids, and in female patients with acute crystal arthritis. MMP-3 serum 
      levels were normal in steroid-free patients with active cutaneo-articular or 
      renal SLE, systemic sclerosis, and vasculitides but were significantly increased 
      in steroid treated patients. MMP-3 levels were normal in fibromyalgia, 
      osteoarthritis, ankylosing spondylitis, and acute inflammatory controls. MMP-3 
      was significantly correlated with CRP in RA (r=0.5, p=0.0004) but not in any of 
      the other disease groups. CONCLUSIONS: MMP-3 serum levels are increased in 
      inflammatory rheumatic diseases characterised by joint synovitis, such as RA, 
      polymyalgia rheumatica, psoriatic arthritis, and acute crystal arthritis-that is, 
      whether the diseases are acute or chronic, erosive or not. They are normal in 
      SLE, systemic sclerosis, and vasculitides as well as in non-rheumatic 
      inflammatory controls, but are significantly increased by steroids. These data 
      strongly suggest that serum MMP-3 reflects synovial inflammation.
FAU - Ribbens, C
AU  - Ribbens C
AD  - Department of Rheumatology, University of Liege, Belgium. Clio.Ribbens@ulg.ac.be
FAU - Martin y Porras, M
AU  - Martin y Porras M
FAU - Franchimont, N
AU  - Franchimont N
FAU - Kaiser, M-J
AU  - Kaiser MJ
FAU - Jaspar, J-M
AU  - Jaspar JM
FAU - Damas, P
AU  - Damas P
FAU - Houssiau, F A
AU  - Houssiau FA
FAU - Malaise, M G
AU  - Malaise MG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Biomarkers)
RN  - 0 (Glucocorticoids)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthritis, Psoriatic/blood
MH  - Arthritis, Rheumatoid/*blood/drug therapy
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - Female
MH  - Fibromyalgia/blood
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Lupus Erythematosus, Systemic/blood
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Osteoarthritis/blood
MH  - Polymyalgia Rheumatica/blood
MH  - Prednisolone/therapeutic use
MH  - Scleroderma, Systemic/blood
MH  - Spondylitis, Ankylosing/blood
MH  - Statistics, Nonparametric
MH  - Vasculitis/blood
PMC - PMC1753989
EDAT- 2002/01/18 10:00
MHDA- 2002/02/13 10:01
PMCR- 2005/02/01
CRDT- 2002/01/18 10:00
PHST- 2002/01/18 10:00 [pubmed]
PHST- 2002/02/13 10:01 [medline]
PHST- 2002/01/18 10:00 [entrez]
PHST- 2005/02/01 00:00 [pmc-release]
AID - 10.1136/ard.61.2.161 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2002 Feb;61(2):161-6. doi: 10.1136/ard.61.2.161.